E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival
(PFS), objective tumor response rate, duration of response, and safety in patients treated
with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally
recurrent or metastatic breast cancer.